Business Wire

Theorem, LLC Launches Theorem Orbital, a New Division Providing an End-to-End Suite of Space and Satellite Logistics Services

4.8.2021 13:00:00 EEST | Business Wire | Press release

Share

Theorem, LLC, an innovation and engineering firm that builds custom enterprise software for the world’s most admired brands, today launched Theorem Orbital, a new division focused on end-to-end space logistics and enablement for the Global 2000.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210804005393/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

“We see space as a major driver of disruption,” Brim-DeForest says. “But in order for our clients to compete, they need help navigating it.” (Graphic: Business Wire)

“Today, only 100 of the Global 2000 have active space programs, but that number will increase tenfold over the next decade,” said Brady Brim-DeForest, CEO of Theorem. “The space industry can seem intimidating and hard to navigate — we are here to help make navigating it easy and transparent.”

While recent space-related startups have focused primarily on delivering launch-side capability, other aspects of the space industry are experiencing significant growth, and game-changing opportunities have become within reach for even those who have made minimal investments to date. These include bespoke satellite programs focused on activities like earth observation, remote sensing, and satellite-enabled communications and connectivity.

Theorem Orbital will leverage its direct relationships with space launch providers, prime contractors and suppliers, universities, and NGOs, allowing for a wide range of services tailored to clients expanding their existing footprint, or building a space strategy from the ground up. Theorem Orbital’s preferred providers for launch services and space-based data today include Rocket Lab, Virgin Orbit, Firefly Aerospace, and Satellogic.

“Our partnership with Theorem will help further our mission of democratizing access to Earth Observation data,” said Thomas VanMatre, Satellogic’s Vice President of Global Business Development. “The combination of Theorem’s world-class software innovation and engineering capabilities and Satellogic’s unit cost advantage will unlock a multitude of use cases for the commercial market.”

As part of its commitment to opening up access to space as a strategic resource for the enterprise, mid-market, and academic markets, Theorem is also announcing a strategic investment into bluShift Aerospace, the Brunswick, Maine based maker of the Starless Rogue launch platform that is designed to enable a low barrier to entry for a diverse collection of payloads into the suborbital space ecosystem.

"bluShift’s approach to developing cost-effective and sustainable next-generation rocket technology will open up space to new markets," said Sascha Deri, CEO of bluShift Aerospace. "We feel that our mission and philosophy are well aligned with Theorem Orbital's commitment to lowering the barrier to entry for companies beginning to leverage space-based infrastructure in their mid and long-term strategic plans. We're pleased to welcome them as an investor, and excited to collaborate on uncovering opportunities to accelerate the adoption of bluShift capabilities within the enterprise market."

At launch, Theorem Orbital’s initial suite of services will include:

  • Satellite Data & Connectivity Strategy and Planning - Strategy services designed to enable clients to leverage data and connectivity generated by existing satellite infrastructure, as well as planning for proprietary constellations.
  • Advanced-Data Analysis - Real-time satellite imagery and remote communication networks are shifting how construction, agriculture, real estate, retail, travel, and mining industries run their daily operations, quarterly planning, risk management, insurance negotiations, and other major drivers of their bottom line. Data providers like Satellogic are opening new use cases daily — Theorem Orbital can help clients make the most of this rapidly evolving field.
  • Software Platform Development - Theorem Orbital designs and builds advanced proprietary software platforms that bring together advanced space-based data sources with existing internal enterprise data and systems.
  • Hardware Development - Theorem Orbital can assist clients in utilizing Satellogic’s unique hosted payload program to rapidly prototype and fly proprietary and commercial off-the-shelf sensors to meet client requirements.
  • Internet-in-Space - Theorem Orbital can assist clients in establishing their own IoT communications network in space including the design and launch of bespoke constellations through preferred launch providers.
  • Launch - Theorem Orbital partners with preferred providers — including Virgin Orbit, Rocket Lab, SpaceX, and more — in order to enable the launch of custom payloads into low-earth and near-earth orbit.

“The cost of putting satellites into space has been dramatically reduced due to the innovations from launch providers such as SpaceX, Rocket Lab, and others,” said Nicolas Spurlock, Director of Corporate Strategy at Theorem. “Now is the time for large enterprises to invest in building their own space-based infrastructure and gain an advantage in the new Space 2.0 era.”

Start charting your course to space by learning more at theoremorbital.com.

About Theorem

Theorem, LLC is an innovation and engineering firm that builds custom software for companies making bold bets to stay ahead. Through research, lean design, and agile delivery, we make great user experiences accessible to the enterprise. Founded in 2007, Theorem’s global cross-functional product development teams drive technology, process, and cultural transformation. To learn more about how we enable ambitious leaders to build better software, visit www.theorem.co or follow @TheoremCo.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Andrew Upah
Theorem, LLC Public Relations
press@theorem.co

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release

JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release

TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye